NCT01934101View on ClinicalTrials.gov

Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 12, 2013

Primary Completion Date

May 28, 2014

Study Completion Date

May 28, 2014

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

CHR-5154

CHR-5154

DRUG

Placebo

Placebo

Trial Locations (1)

BT2 7BA

GSK Investigational Site, Belfast

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01934101 - Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter